

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Caligiuri et al.	
Serial No.:	10/589,840	Art Unit: 1628
Filed:	May 17, 2007	Examiner: A. Pagonakis
Entitled:	METHODS FOR TREATING RESISTANT OR REFRACTORY TUMORS	

Attorney Docket No.: GPC-298.1P US

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §§ 1.56, 1.97, AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

This information disclosure statement is filed pursuant to 37 CFR §§ 1.97(e)(1). Accordingly, no fee is required with this submission. The Commissioner is hereby authorized to charge payment of any fee determined to be required in connection with the filing of this paper to Deposit Account No. 50-0268. A listing of the cited documents (modified USPTO Form 1449) is also enclosed.

**Non-Patent Literature Documents**

Japanese Office Action issued May 10, 2011 (JP Appl. No. 2006-553558);

Belani, C.P., "Docetaxel in Combination with Platinum Compounds for Non-Small-Cell Lung Cancer", *Clinical Lung Cancer*, 1(1): S10-S14 (2000);

Ferrante et al., "Promising New Developments in Cancer Chemotherapy", *Cancer Chemother. Pharmacol.*, 43(Suppl.): S61-S68 (1999);

**Non-Patent Literature Documents**

Herrada et al., "Remission with Carboplatin of Paclitaxel Resistant Primary Peritoneal Papillary Serous Carcinoma: Case Report", *Eur. J. Gynec. Oncol.*, XVIII, α, 1 (1997);

Pu et al., "Cross-Resistance and Combined Cytotoxic Effects of Paclitaxel and Cisplatin in Bladder Cancer Cells", *Journal of Urology*, 165: 2082-2085 (2001);

Rosell et al., "Predicting Response to Paclitaxel/Carboplatin-Based Therapy in Non-Small Cell Lung Cancer", *Seminars in Oncology*, 28(4) (Suppl. 14): 37-44 (2001);

Schinkel et al., "Multidrug Resistance and the Role of P-glycoprotein Knockout Mice", *European Journal of Cancer*, 31A (7/8): 1295-1298 (1995);

Thigpen et al., "Cisplatin as Second-Line Therapy in Ovarian Carcinoma Treated Initially with Single-Agent Paclitaxel: a Gynecologic Oncology Group Study", *Gynecologic Oncology*, 90: 581-586 (2003);

Weiss et al., "New Cisplatin Analogues in Development", *Drugs*, 46(3): 360-377 (1993).

Each item contained, herein was first cited in a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Applicants do not intend to represent that any of the documents submitted herein is material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicants respectfully request that the documents submitted herein be considered and made of record in this application, and also printed on any patent issuing from the above-identified application.

Respectfully submitted,

/David G. O'Brien/

David G. O'Brien, Reg. No. 46,125  
Leon R. Yankwich, Reg. No. 30,237  
Attorneys for Applicants  
YANKWICH & ASSOCIATES, P.C.  
201 Broadway  
Cambridge, Massachusetts 02139  
telephone: (617) 374-3700  
telefax: (617) 374-0055

**Certificate of Transmission via EFS-Web**

The undersigned hereby certifies that this correspondence and accompanying documents are being electronically submitted to the U.S. Patent Office on **August 9, 2011.**

**/David G. O'Brien/  
Reg. No. 46,125**